Warner Chilcott plc today
announced that the FDA has
approved its next generation ACTONEL (risedronate sodium) product for the
treatment of postmenopausal osteoporosis in the United States. The product will be
marketed as ATELVIAT (risedronate sodium) delayed-release tablets.
“The approval of ATELVIA represents an exciting
addition to the ACTONEL franchise, as well as our women’s healthcare product portfolio.
We believe the dosing convenience of ATELVIA sets it apart from other treatment
options for osteoporosis patients and provides an opportunity to regain market
share in the U.S.
in this segment,” said Roger Boissonneault, President and CEO of Warner
Chilcott.
The company anticipates the commercial launch of ATELVIA in
early 2011.
